EVRY, France--(BUSINESS WIRE)--IntegraGen (FR0010908723 - ALINT), a leading player in genome analysis and the development and commercialization of molecular diagnostic tests for autism and oncology, announced today the signing of a distribution agreement with Genoma SA allowing the company to commercialize the autism spectrum disorder genetic risk assessment test IntegraGen has developed.
"Thanks to this agreement between Genoma and IntegraGen, physicians outside the U.S. will now be able to offer parents a genetic predisposition test for autism for their children who have developmental delays,” stated Dr. Bernard Courtieu, IntegraGen’s CEO. “This test will enable the earlier referral and diagnosis of children with autism spectrum disorder and aid clinicians to implement appropriate treatments when they are most effective, before the age of three years. We are particularly pleased that Genoma will market the test in Europe and in other markets outside of the United States. With many children in France and around the world being diagnosed with autism at an age which is too late to implement early interventional treatment options shown to improve outcomes, the utilization of this test will contribute to an earlier clinical diagnosis and improve the care of children with autism spectrum disorder.”
Help employers find you! Check out all the jobs and post your resume.
"Thanks to this agreement between Genoma and IntegraGen, physicians outside the U.S. will now be able to offer parents a genetic predisposition test for autism for their children who have developmental delays,” stated Dr. Bernard Courtieu, IntegraGen’s CEO. “This test will enable the earlier referral and diagnosis of children with autism spectrum disorder and aid clinicians to implement appropriate treatments when they are most effective, before the age of three years. We are particularly pleased that Genoma will market the test in Europe and in other markets outside of the United States. With many children in France and around the world being diagnosed with autism at an age which is too late to implement early interventional treatment options shown to improve outcomes, the utilization of this test will contribute to an earlier clinical diagnosis and improve the care of children with autism spectrum disorder.”
Help employers find you! Check out all the jobs and post your resume.
